Breaking News, Collaborations & Alliances

Ligand Forms Multi-Program LTP Technology Licensing Agreement

Newly-formed Nucorion, co-founded by Ligand, to pursue a pipeline of LTP-based programs for China and other markets

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ligand Pharmaceuticals has signed a license agreement for three programs utilizing Ligand’s LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, a venture-funded biotechnology company focused on developing anti-cancer and anti-viral agents initially directed to China. Ligand’s LTP technology is a novel prodrug technology platform designed to selectively deliver a range of active pharmaceutical agents to the liver. By directly targeting the liver, the goal is to maximize eff...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters